Scarica l'app Stockscreener
20.00
5.82%
1.10
Precedente Chiudi:
$18.90
Aprire:
$18.85
Volume 24 ore:
183.56K
Relative Volume:
1.65
Capitalizzazione di mercato:
$168.78M
Reddito:
Utile/perdita netta:
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
1 W Prestazione:
+0.65%
1M Prestazione:
-21.57%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$18.16
$20.94
Portata 52W:
$18.16
$44.28
Yarrow Bioscience, Inc. Common Stock Stock (YARW) Company Profile
Nome
Yarrow Bioscience, Inc. Common Stock
Settore
Industria
Telefono
-
Indirizzo
-
Compare YARW vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
YARW
Yarrow Bioscience, Inc. Common Stock
|
20.00 | 168.78M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Yarrow Bioscience, Inc. Common Stock Stock (YARW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-03 | Iniziato | BTIG Research | Buy |
| 2025-07-31 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-11-18 | Iniziato | BTIG Research | Buy |
| 2021-12-06 | Ripresa | H.C. Wainwright | Buy |
Yarrow Bioscience, Inc. Common Stock Borsa (YARW) Ultime notizie
A passive investor reports ownership of 1 million Yarrow Bioscience (YARW) shares. - Stock Titan
Raymond Debbane Reports 675,000 Shares in Yarrow Bioscience (NASDAQ: YARW) Representing 7.2% Passive Stake - Kalkine Media
New investor group tops 5% in Yarrow Bioscience (YARW) - Stock Titan
Yarrow Bioscience (NASDAQ: YARW) Grants Underwriters 30-Day Option for 865,384 Additional Shares - Kalkine Media
Yarrow Bioscience Raises About $161.8 Million in Public Stock Offering at $26 Per Share - TradingView
Yarrow Bioscience Files Prospectus for 25.78 Million Warrant-Linked Shares Offering (NASDAQ: YARW) - Kalkine Media
Yarrow Bioscience launches public offering of common stock - Investing.com India
Yarrow Bioscience Launches Public Offering of Common Stock - Yahoo Finance
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering - Business Wire
Yarrow Bioscience prices $150M public offering at $26/share - Investing.com
Yarrow Bioscience Announces Proposed Underwritten Public Offering - Business Wire
YARW SEC FilingsYarrow Bioscience, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
OrbiMed Advisors Discloses Investment at Yarrow Bioscience with 9.97% Stake - TradingView
Yarrow Bioscience Alters Capital Structure With Warrant Exchange - TipRanks
Yarrow Bioscience, Inc. (YARW) Company Information - Simply Wall Street
Yarrow Bioscience (Nasdaq:YARW)Stock Analysis - Simply Wall Street
Yarrow Bioscience Completes VYNE Merger and Nasdaq Debut - TipRanks
Yarrow Bioscience Completes VYNE Merger and $200 Million Private Financing - citybiz
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease - Yahoo Finance
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience - Yahoo Finance
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split, $17.3M Special Dividend, and Merger with Yarrow Bioscience – Minichart - Minichart
VYNE Sets $17.3M Cash Dividend Before Expected Yarrow Merger - Stock Titan
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience - Yahoo Finance
VYNE Therapeutics and Yarrow Bioscience Announce Merger to Advance YB-101 for Graves' Disease and Thyroid Eye Disease - Quiver Quantitative
New biotech merger backs antibody targeting Graves’ and thyroid eye disease - Stock Titan
Yarrow Bioscience, Inc. Common Stock Azioni (YARW) Dati Finanziari
Non sono disponibili dati finanziari per Yarrow Bioscience, Inc. Common Stock (YARW). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):